Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
The Journal of Clinical Endocrinology and Metabolism|July 28, 2012
Effects of exercise on sRAGE levels and cardiometabolic risk factors in patients with type 2 diabetes: a randomized controlled trialKyung Mook Choi, Kyung Ah Han, Hee Jung Ahn, et al.
Communications Biology|September 30, 2021
SALM4 negatively regulates NMDA receptor function and fear memory consolidationEunkyung Lie, Yeji Yeo, Eun-Jae Lee, et al.
Diabetes, Obesity & Metabolism|March 8, 2024
A 52-week efficacy and safety study of enavogliflozin versus dapagliflozin as an add-on to metformin in patients with type 2 diabetes mellitus: ENHANCE-M extension studyTae Seo Sohn, Kyung-Ah Han, Yonghyun Kim, et al.
Diabetes Care|April 17, 2015
Improvement of Nonalcoholic Fatty Liver Disease With Carnitine-Orotate Complex in Type 2 Diabetes (CORONA): A Randomized Controlled TrialJi Cheol Bae, Won Young Lee, Kun Ho Yoon, et al.
Diabetes & Metabolism Journal|October 28, 2025
Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled TrialJun Hwa Hong, Kyung Ah Han, You-Cheol Hwang, et al.
Diabetes, Obesity & Metabolism|September 14, 2016
Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study)Soo Lim, Kyung Ah Han, JaeMyung Yu, et al.
Clinical Endocrinology|October 17, 2012
The effects of caloric restriction on fetuin-A and cardiovascular risk factors in rats and humans: a randomized controlled trialKyung Mook Choi, Kyung Ah Han, Hee Jung Ahn, et al.
Diabetes & Metabolism Journal|February 9, 2023
Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized TrialKyung Ah Han, Yong Hyun Kim, Doo Man Kim, et al.
Diabetes, Obesity & Metabolism|June 5, 2018
Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trialKyung-Ah Han, Suk Chon, Choon Hee Chung, et al.
Diabetes, Obesity & Metabolism|March 5, 2023
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trialSoo Heon Kwak, Kyung Ah Han, Kyung-Soo Kim, et al.
Pageof 8